Luteinizing hormone-releasing hormone (LHRH) analogue

DRUG3 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

Metastatic Castration-resistant Prostate CancerProstate Cancer

Phase 2

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

RecruitingNCT06059118

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsProstate Cancer

Start: 2023-10-04End: 2029-11-30Target: 50Updated: 2026-01-14

The COSMYC Trial (COmbined Suppression of MYC)

RecruitingNCT06922318

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMetastatic Castration-resistant Prostate Cancer

Start: 2025-08-19End: 2031-08-30Target: 50Updated: 2026-06-18

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

RecruitingNCT07142551

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMetastatic Castration-resistant Prostate Cancer

Start: 2026-03-09End: 2034-06-01Target: 60Updated: 2026-03-11